TRU-SENTIMENT ยท DeltaNeutral
MRK Trading Analysis - 11/13/2026 11:41 AM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
MRK (Merck & Co. Inc.) at $146.51. True Sentiment Bullish, delta 40-60 call 78% / put 22%, call $719,082 vs put $202,725. RSI 53.3.
- Symbol
- MRK
- Price
- $146.51
- Article bias (separate from True Sentiment)
- bullish
- Conviction
- medium
- Published
- 2026-11-13 11:41:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From MRK_options_20261113: sentiment Bullish. Call dollar vol 719,082.00 (78.0%), Put 202,725.00 (22.0%), total 921,807.00. Calls 796 contracts vs 338 puts.
Call Volume: 719,082.00 (78.0%) Put Volume: 202,725.00 (22.0%) Total: 921,807.00
Pure directional conviction (delta 40-60 filter, 2.6% of chain) shows strong call lean. Near-term expectations: upward bias to ~150+ strikes (Dec 18 call 150 bid 3.50). No divergence from technicals (both mildly bullish).
Key Statistics: MRK
Fundamental Snapshot
Valuation
| P/E (trailing) | 148.00 |
| EPS (trailing 12 mo) | $0.99 |
| Market cap | $360.84B |
| Shares outstanding | 2,465.2M |
Dividend
| Dividend yield | 2.31% |
| Annual dividend | $3.40 |
| Ex-dividend date | 2026-09-15 |
Risk & range
| Beta | -0.05 |
| 52-week low | $90.90 |
| 52-week high | $156.92 |
| Historical volatility | 32.4% |
Ownership & trading
| Institutional ownership | 54.3% |
| Average daily volume | 9.9M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are based on general knowledge and are separated from the data-driven analysis below.
- Merck (MRK) recently advanced its oncology pipeline with positive Phase 3 readouts for an investigational KEYTRUDA combination, reinforcing long-term growth narrative.
- Analysts noted pending FDA decisions on MRK's HPV vaccine expansion indications, a potential near-term catalyst.
- MRK declared its routine quarterly dividend (ex-dividend Sept 15, 2026 per fundamentals),็ปดๆ shareholder yield appeal amid pharma sector rotation.
- Broader macro: defensive pharma flows increased as rates stabilized; MRK's negative beta (-0.05) suggests low correlation to broader equity swings.
- No explicit earnings date in provided data, but historical Dec fiscal year-end (2025-12-01) implies upcoming annual reporting season as a watch item.
Context: These headlines support a stable fundamental backdrop that aligns with the bullish options sentiment observed in the embedded data, though technicals show compression near mid-range.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS JSON:
- Trailing P/E is 148.00 with trailing EPS of 0.99; valuation appears elevated versus typical pharma peers, though no PEG (null) or forward PE (null) provided for relative comparison.
- Dividend yield 2.31% with rate 3.40; ex-dividend 2026-09-15. Provides income context.
- Market cap 360.84B, shares outstanding 2.46B, institutional ownership 54.31%.
- Beta -0.05 (negative, defensively skewed). 52-week high 156.92, low 90.90.
- Historical volatility 32.41%; average volume 9.88M.
- Missing from data: revenue growth, margins (gross/operating/net), ROE, debt/equity, FCF, analyst target (all null). Cannot assess profitability trends or leverage.
- Fundamentals show high multiple but defensive beta; technicals (price 147.29, SMA aligned) and sentiment (bullish options) diverge from rich P/E by suggesting near-term upward positioning rather than value.
Current Market Position
Current price per indicators: 147.29 (as of 2026-11-12 close). Minute bars show 2026-11-12 open 148.61, low 146.98, close ~147.29; 2026-11-13 11:10 bar close 146.52, intraday drifting lower from 148.61 to 146.52.
Recent daily: 30-day range high 154.02 (2026-10-22), low 138.80 (2026-10-05). Price sits mid-range.
Intraday momentum: minute bars 11-13 show lower highs (146.66 to 146.52), volume thinning (~38K-61K), slight bearish intraday bias vs prior day.
Technical Analysis
Technical Indicators
SMA alignment: 5 > 20 > 50 (147.42 > 146.40 > 146.25), mild bullish stacking, no bear cross. Price above all SMAs.
RSI 53.26 = neutral-positive momentum, no overbought. MACD positive histogram 0.10 = slight bullish bias. Bollinger mid 146.40, price just above; no squeeze (band width 11.25). 30-day range: price 147.29 is 56% up from low (138.80) to high (154.02).
True Sentiment Analysis (Delta 40-60 Options)
From MRK_options_20261113: sentiment Bullish. Call dollar vol 719,082.00 (78.0%), Put 202,725.00 (22.0%), total 921,807.00. Calls 796 contracts vs 338 puts.
Call Volume: 719,082.00 (78.0%) Put Volume: 202,725.00 (22.0%) Total: 921,807.00
Pure directional conviction (delta 40-60 filter, 2.6% of chain) shows strong call lean. Near-term expectations: upward bias to ~150+ strikes (Dec 18 call 150 bid 3.50). No divergence from technicals (both mildly bullish).
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.